Influenza Epidemiology and Vaccine Effectiveness Following Funded Influenza Vaccine in Queensland, Australia, 2022

被引:1
|
作者
Shrestha, Ashish C. [1 ,2 ]
Field, Emma [2 ]
Thangarajah, Dharshi [3 ]
Andrews, Ross [1 ,2 ]
Ware, Robert S. [4 ]
Lambert, Stephen B. [1 ,2 ,5 ]
机构
[1] Queensland Hlth, Queensland Publ Hlth & Sci Serv, Brisbane, Qld, Australia
[2] Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT, Australia
[3] Dept Hlth & Aged Care, Canberra, ACT, Australia
[4] Griffith Univ, Griffith Biostat Unit, Brisbane, Qld, Australia
[5] Natl Ctr Immunisat Res & Surveillance, Sydney, NSW, Australia
关键词
Australia; flu; influenza; influenza vaccine; Queensland; vaccine effectiveness; COVERAGE;
D O I
10.1111/irv.70007
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: In 2022, publicly funded influenza vaccine was made available to all residents of Queensland, Australia. This study compared influenza epidemiology in 2022 with previous years (2017-2021) and estimated influenza vaccine effectiveness (VE) during 2022. Methods: The study involved a descriptive analysis of influenza notifications and a case-control study to estimate VE. Cases were notifications of laboratory-confirmed influenza, and controls were individuals who were test negative for COVID-19. Cases and controls were matched on age, postcode and specimen collection date. VE against hospitalisation was investigated by matching hospitalised cases to controls. Conditional logistic regression models were adjusted for sex. Results: In 2022, Queensland experienced an early influenza season onset (April-May) and high case numbers (n = 45,311), compared to the previous 5 years (annual average: 29,364) and 2020-2021 (2020:6047; 2021:301) during the COVID-19 pandemic. Adjusted VE (VE(ad)j) against laboratory-confirmed influenza was 39% (95% confidence interval [CI]: 37-41), highest for children aged 30 months to < 5 years (61%, 95% CI: 49-70) and lowest for adults aged >= 65 years (24%, 95% CI: 17-30). VEadj against influenza-associated hospitalisation was 54% (95% CI: 48-59). Among children < 9 years of age, VEadj against laboratory-confirmed influenza (55%, 95% CI: 49-61) and hospitalisation (67%, 95% CI: 39-82) was higher in those who received a complete dose schedule. Conclusion: In Queensland, the 2022 influenza season started earlier than the previous 5 years. VE against influenza notifications varied across age groups. VE estimates against influenza-associated hospitalisation were higher than those against laboratory-confirmed influenza.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Effectiveness of quadrivalent influenza vaccination in the first year of a funded childhood program in Queensland, Australia, 2018
    Thangarajah, Dharshi
    Malo, Jonathan A.
    Field, Emma
    Andrews, Ross
    Ware, Robert S.
    Lambert, Stephen B.
    VACCINE, 2021, 39 (04) : 729 - 737
  • [22] Cost Effectiveness of Influenza Vaccine for US Children Live Attenuated and Inactivated Influenza Vaccine
    Shim, Eunha
    Brown, Shawn T.
    DePasse, Jay
    Nowalk, Mary Patricia
    Raviotta, Jonathan M.
    Smith, Kenneth J.
    Zimmerman, Richard K.
    AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2016, 51 (03) : 309 - 317
  • [23] Influenza epidemiology and influenza vaccine effectiveness during the 2016–2017 season in the Global Influenza Hospital Surveillance Network (GIHSN)
    Víctor Baselga-Moreno
    Svetlana Trushakova
    Shelly McNeil
    Anna Sominina
    Marta C. Nunes
    Anca Draganescu
    Serhat Unal
    Parvaiz Koul
    Jan Kyncl
    Tao Zhang
    Ainagul Kuatbayeva
    Afif Ben-Salah
    Elena Burtseva
    Joan Puig-Barberà
    Javier Díez-Domingo
    BMC Public Health, 19
  • [24] Pooled influenza vaccine effectiveness estimates for Australia, 2012-2014
    Sullivan, S. G.
    Carville, K. S.
    Chilver, M.
    Fielding, J. E.
    Grant, K. A.
    Kelly, H.
    Levy, A.
    Stocks, N. P.
    Tempone, S. S.
    Regan, A. K.
    EPIDEMIOLOGY AND INFECTION, 2016, 144 (11): : 2317 - 2328
  • [25] Influenza epidemiology, vaccine coverage and vaccine effectiveness in children admitted to sentinel Australian hospitals in 2014: the Influenza Complications Alert Network (FluCAN)
    Blyth, C. C.
    Macartney, K. K.
    Hewagama, S.
    Senenayake, S.
    Friedman, N. D.
    Simpson, G.
    Upham, J.
    Kotsimbos, T.
    Kelly, P.
    Cheng, A. C.
    EUROSURVEILLANCE, 2016, 21 (30): : 25 - 33
  • [26] Influenza and the influenza vaccine
    MacDonald, Noni
    Weir, Erica
    Langley, Joanne M.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2007, 177 (09) : 1028 - 1028
  • [27] Influenza Vaccine Effectiveness in the Community and the Household
    Ohmit, Suzanne E.
    Petrie, Joshua G.
    Malosh, Ryan E.
    Cowling, Benjamin J.
    Thompson, Mark G.
    Shay, David K.
    Monto, Arnold S.
    CLINICAL INFECTIOUS DISEASES, 2013, 56 (10) : 1363 - 1369
  • [28] Repeat vaccination and influenza vaccine effectiveness
    Cowling, Benjamin J.
    Zhong, Shuyi
    LANCET RESPIRATORY MEDICINE, 2023, 11 (01): : 2 - 3
  • [29] Confounding in evaluating the effectiveness of influenza vaccine
    Mori, Mitsuru
    Oura, Asae
    Ohnishi, Hirofumi
    Washio, Masakazu
    VACCINE, 2008, 26 (50) : 6459 - 6461
  • [30] Influenza vaccine effectiveness, 2010/11
    Steens, A.
    van der Hoek, W.
    Dijkstra, F.
    van der Sande, M.
    EUROSURVEILLANCE, 2011, 16 (15): : 23 - 24